Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 26, 2024

SELL
$62.76 - $81.61 $1,443 - $1,877
-23 Reduced 1.03%
2,212 $167,000
Q1 2024

Apr 18, 2024

BUY
$72.35 - $88.99 $13,674 - $16,819
189 Added 9.24%
2,235 $167,000
Q4 2023

Jan 25, 2024

BUY
$42.42 - $80.28 $2,375 - $4,495
56 Added 2.81%
2,046 $150,000
Q3 2023

Oct 27, 2023

BUY
$39.12 - $49.85 $77,848 - $99,201
1,990 New
1,990 $91,000
Q2 2023

Jul 18, 2023

BUY
$23.58 - $44.68 $51,192 - $97,000
2,171 New
2,171 $91,000
Q2 2022

Jul 25, 2022

SELL
$7.4 - $15.07 $33,004 - $67,212
-4,460 Reduced 60.51%
2,911 $39,000
Q1 2022

May 02, 2022

BUY
$11.65 - $19.57 $31,443 - $52,819
2,699 Added 57.77%
7,371 $102,000
Q4 2021

Jan 28, 2022

BUY
$18.01 - $30.1 $84,142 - $140,627
4,672 New
4,672 $88,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.